Catheter-Related Bloodstream Infection (CRBSI) Market Size in the 7MM is Projected to Increase Significantly by 2036, Estimates DelveInsight

The market dynamics for Catheter-Related Bloodstream Infection (CRBSI) are witnessing substantial growth driven by the increasing use of intravascular catheters in hospital and critical care settings, rising incidence of healthcare-associated infections, improving infection surveillance and diagnostic practices, and greater adoption of antimicrobial and catheter management strategies. Additionally, the anticipated introduction of novel targeted therapies such as Mino-Lok is expected to further transform the CRBSI treatment landscape during the forecast period.

DelveInsight's "Catheter-Related Bloodstream Infection (CRBSI) Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of CRBSI, historical and forecasted epidemiology, as well as the CRBSI market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the CRBSI Market Report
• The CRBSI market size in the 7MM is expected to increase significantly during the forecast period (2026-2036).
• According to DelveInsight estimates, the CRBSI market is anticipated to grow owing to the increasing launch of emerging therapies, complex medical conditions, and the increased use of central venous catheters.
• In November 2023, CorMedix reported that the US FDA approved DEFENCATH, the first and only antimicrobial catheter lock solution in the US. DEFENCATH demonstrated up to 71% reduction in the risk of CRBSIs in a Phase III clinical study.
• DelveInsight estimated more than 1 million CRBSI cases in the US in 2025, highlighting the infection's substantial burden and the need for improved prevention, diagnosis, and treatment strategies.
• The incidence of CRBSI in the US reflects a diverse microbial profile, with Gram-negative bacteria accounting for ~40% of cases, Gram-positive bacteria for ~30%, and Candida species for ~30% of cases.
• A study analyzing CRBSI in central venous catheter patients in Japan found an overall incidence rate of 1.35 cases per 1,000 catheter-days.
• A study in Germany reported an overall incidence density of approximately 1.27 cases per 1,000 central venous catheter days, while hematology ICUs showed significantly higher rates at 4.43 per 1,000 catheter days.
• The leading CRBSI companies such as CorMedix, Citius Pharmaceuticals, and others are actively developing innovative therapies.
• Promising CRBSI pipeline therapies such as Mino-Lok are expected to reshape the treatment landscape.

Stay ahead in the CRBSI Therapeutics Market with DelveInsight's Strategic Report at https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Catheter-Related Bloodstream Infection (CRBSI)?
Catheter-Related Bloodstream Infection (CRBSI) is a hospital-acquired bacteremia associated with intravascular catheters. It develops when microorganisms colonize the catheter surface and form bacterial biofilms, which reduce antimicrobial susceptibility and make infections difficult to treat. CRBSI is commonly caused by coagulase-negative staphylococci, Staphylococcus aureus, enteric gram-negative bacilli, enterococci, streptococci, Pseudomonas, and Candida species.

Risk factors for CRBSI include immune deficiency, chemotherapy-induced neutropenia, chronic diseases such as diabetes, disruption of the skin barrier, prolonged catheter use, and critically ill or very-low-birth-weight patients. Diagnosing CRBSI requires clinical assessment, microbiological cultures from blood and catheter samples, and imaging studies to identify the pathogen and determine catheter involvement.

The current CRBSI treatment landscape remains limited, with only one approved therapy available. Emerging therapies such as Mino-Lok highlight ongoing efforts to address unmet needs through novel antimicrobial and catheter-salvage strategies aimed at improving patient outcomes and reducing infection-associated complications.

CRBSI Epidemiology Segmentation in the 7MM
• Total Incident Cases of CRBSI
• Incident Cases of CRBSI caused by Causative Pathogens
• Treatable Cases of CRBSI
• Country-specific Incident Cases of CRBSI
• Pathogen-specific Cases of CRBSI
• Total Hospitalization Cases associated with CRBSI

Download the report to understand which factors are driving CRBSI epidemiology trends.
https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

CRBSI Marketed Drugs

DEFENCATH (taurolidine and heparin): CorMedix
DEFENCATH is an FDA-approved antimicrobial catheter lock solution designed to reduce the occurrence of CRBSIs in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DEFENCATH combines antimicrobial and anticoagulant properties and demonstrated up to 71% reduction in CRBSI risk in a Phase III clinical study. The product has received Fast-track designation (FTD) and Qualified Infectious Disease Product (QIDP) designation from the US FDA.

CRBSI Drugs and Companies
• CorMedix: DEFENCATH (taurolidine and heparin)
• Citius Pharmaceuticals: Mino-Lok
To learn more about CRBSI treatment guidelines, visit https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the CRBSI Market
• Increasing use of central venous catheters: Growing use of intravascular catheters in hospitals, oncology care, hemodialysis, and critical care settings is increasing infection risk and driving demand for effective therapies.
• Rising burden of healthcare-associated infections: The growing incidence of healthcare-associated infections and antibiotic resistance is contributing to the expanding CRBSI patient population.
• Advancements in antimicrobial catheter lock therapies: Development of innovative antimicrobial and catheter-salvage solutions is improving treatment approaches and patient management.
• Expanding adoption of infection prevention strategies: Increased focus on infection surveillance, catheter management protocols, and preventive measures is supporting market growth.
• Emerging pipeline therapies: Investigational therapies such as Mino-Lok are expected to address significant unmet needs in CRBSI treatment and prevention.
Recent Developments in the CRBSI Market
• In November 2024, Citius Pharmaceuticals reported a productive Type C meeting with the US FDA regarding Mino-Lok's Phase III trial data and future submission pathway for CRBSI treatment.
• In November 2023, CorMedix announced the US FDA approval of DEFENCATH for reducing CRBSI risk in adult hemodialysis patients using central venous catheters.
• Mino-Lok's Phase III trial successfully met both primary and secondary endpoints, demonstrating strong catheter salvage outcomes and favorable safety results.
• CorMedix secured patent protection for DEFENCATH until April 2042 through USPTO-granted intellectual property rights.

Scope of the CRBSI Market Report
• Coverage: 7MM
• Study Period: 2022-2036
• CRBSI Companies: CorMedix, Citius Pharmaceuticals, and others
• CRBSI Pipeline Therapies: Mino-Lok and others
• CRBSI Market Dynamics: Market Drivers and Barriers
• CRBSI Market Access and Reimbursement
• CRBSI Unmet Needs and Future Perspectives

Discover more about CRBSI drugs in development at https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
• CRBSI Market Report Introduction
• Executive Summary of CRBSI
• SWOT Analysis of CRBSI
• CRBSI Market Overview at a Glance
• Disease Background and Overview
• CRBSI Epidemiology and Patient Population
• Country-Specific Patient Population of CRBSI
• CRBSI Current Treatment and Medical Practices
• CRBSI Unmet Needs
• CRBSI Emerging Therapies
• CRBSI Market Outlook
• Country-Wise CRBSI Market Analysis (2022-2036)
• CRBSI Market Access and Reimbursement
• CRBSI Market Drivers
• CRBSI Market Barriers
• CRBSI Appendix
• CRBSI Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.